Appendix B: Provincial Case Definitions for Reportable Diseases

Disease: Anthrax

Revised December 2014
Anthrax

1.0 Provincial Reporting
Confirmed, probable and suspect cases of disease

2.0 Type of Surveillance
Case-by-case

3.0 Case Classification

3.1 Confirmed Case
Laboratory confirmation of infection with clinically compatible signs and symptoms:
  • Culture of *Bacillus anthracis* from a clinical specimen (e.g., blood)
    OR
  • Identification of *B. anthracis* in a clinical specimen (e.g., blood) using the fluorescent antibody technique

3.2 Probable Case
Clinically compatible signs and symptoms in a person in whom *B. anthracis* deoxyribonucleic acid (DNA) is detected and with an epidemiologic link to a confirmed case or suspected source.

3.3 Suspect Case
Clinically compatible signs and symptoms in a person with an epidemiologic link to a confirmed case or suspected source.

4.0 Laboratory Evidence

4.1 Laboratory Confirmation
Any of the following will constitute a confirmed case of Anthrax:
  • Positive *B. anthracis* culture with confirmation (See Section 4.2)
  • Positive *B. anthracis* direct fluorescent antibody (DFA) test

4.2 Approved/Validated Tests
  • Standard culture for *B. anthracis* with confirmation
  • DFA for *B. anthracis*
  • Nucleic acid amplification test (NAAT) for *B. anthracis*
• Confirmatory methods include combinations of Gram stain, motility, morphology, haemolysis, spores, demonstration of capsule and lysis by gamma phage

4.3 Indications and Limitations
Potential for false negative NAAT exists if virulence gene is lacking.

5.0 Clinical Evidence
Three clinical forms are recognized: cutaneous, inhalational and gastrointestinal:
• With the cutaneous form, the skin begins to itch and a papule appears at the inoculation site, followed by formation of a vesicle. Within two to six days the vesicle develops into a depressed black eschar accompanied by swelling. If inoculation site involves face or neck, swelling may involve obstruction of airway. Untreated infections can spread to lymph nodes or meninges and result in septicemia.
• The inhalational form begins with fever, malaise, a mild cough or chest pain. Three to four days later the symptoms of respiratory distress appear (including cyanosis, shock and excessive sweating), followed by death.
• Gastrointestinal anthrax is rare and usually occurs in food poisoning outbreaks where patients experience abdominal pain, nausea and vomiting, followed by fever, septicemia and death.

6.0 ICD Code(s)

6.1 ICD-10 Code(s)
A22

7.0 Comments
N/A

8.0 Sources
9.0 Document History

Table 1: History of Revisions

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Document Section</th>
<th>Description of Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2014</td>
<td>General</td>
<td>New template.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nucleic acid amplification test abbreviation“(NAT)” replaced with “(NAAT)” throughout document.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 8.0 title changed from “References” to “Sources”.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Section 9.0 Document History added.</td>
</tr>
<tr>
<td>December 2014</td>
<td>4.3 Indications and Limitations</td>
<td>Bullet one converted into sentence format.</td>
</tr>
<tr>
<td>December 2014</td>
<td>5.0 Clinical Evidence</td>
<td>Entire section revised.</td>
</tr>
<tr>
<td>December 2014</td>
<td>6.0 ICD Code(s)</td>
<td>Subheading added, “6.1 ICD-10 Code(s)” with “A22” listed as normal text below.</td>
</tr>
<tr>
<td>December 2014</td>
<td>8.0 Sources</td>
<td>Updated.</td>
</tr>
</tbody>
</table>